Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes

Published:2019-03 Issue:3 Volume:41 Page:445-455.e4
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Cheng Huafeng,Wan Xu,Ma Jing,Wu Bin

Funder

National Natural Science Foundation of China

Shanghai Municipal Health Commission

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference37 articles.

1. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016;Lancet,2017

2. Prevalence and control of diabetes in Chinese adults;Xu;JAMA,2013

3. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013;Wang;JAMA,2017

4. The economic burden of inpatients with type 2 diabetes: a case study in a Chinese hospital;Wang;Asia Pac J Public Health,2015

5. Diabetes in China: a societal solution for a personal challenge;Chan;Lancet Diabetes Endocrinol,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug events in cost-effectiveness models of pharmacological interventions for diabetes, diabetic retinopathy, and diabetic macular edema: a scoping review;JBI Evidence Synthesis;2024-07-29

2. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes;Diabetology;2023-10-13

3. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model;Frontiers in Public Health;2023-09-06

4. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China;Frontiers in Endocrinology;2021-08-13

5. Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study;Acta Diabetologica;2020-10-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3